Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Thoracic 3Head & Neck 2Dermatologic 2Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 1

Interventions

pembrolizumab 12Specimen Handling 8Biopsy 8Magnetic Resonance Spectroscopy 7Paclitaxel 6trastuzumab deruxtecan 4Fluorouracil 4Bevacizumab 4durvalumab 3Pemetrexed 3Oxaliplatin 3Leucovorin 3Exercise 3Cetuximab 3Carboplatin 3Capecitabine 3Blood Specimen Collection 3trametinib 2olaparib 2nilotinib 2dostarlimab 2cabozantinib 2X-Rays 2Temozolomide 2Standard of Care 2Radiosurgery 2Nivolumab 2Irinotecan 2Cisplatin 2zolbetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
avelumab × Tumor-Agnostic × 30 days × Clear all
NCT05396833 2026-05-28

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

EMD Serono

Phase 1 Active not recruiting
120 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡